AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
SAFE is a life sciences company composed of a proficient team of entrepreneurs, leaders in the pharmaceutical industry, and former high-ranking government officials. The company is focused on building a robust portfolio of harm reduction solutions that take a prevent, protect and prevail approach.
SAFE’s current portfolio of harm reduction solutions includes an FDA cleared neuromodulation device for opioid withdrawal symptoms, life saving naloxone hydrochloride products, fentanyl testing devices and a pipeline of synthetic agonists aimed at treating addiction.
Summary of the Proposed Transaction
Pursuant to the Agreement, the Company and SAFE intend to complete a business combination by way of a three-cornered amalgamation pursuant to the provisions of the Business Corporations Act (Ontario). The structure of the Proposed Transaction remains subject to change in accordance with the Company and SAFE each receiving further legal and tax advice. The Agreement will be followed by the good faith negotiation of definitive documentation, including a definitive merger, amalgamation, arrangement, business combination or share exchange agreement, which will address matters that have not yet been discussed in addition to the matters set out in the Agreement. The shareholders of SAFE (the “SAFE Shareholders”), other than the SAFE Shareholders who exercise their dissent rights, will receive, subject to adjustment, one common share in the capital of the Company (a “Company Share”) (on a post-Company consolidation or stock split basis, as applicable) for each common share of SAFE held.
As a condition precedent of the Proposed Transaction, the Company’s board of directors will approve a consolidation or stock split of the Company’s issued and outstanding share capital at a ratio to be determined.
The completion of the Proposed Transaction is subject to the satisfaction of various conditions, including but not limited to: (i) the approval of the Proposed Transaction by the requisite majority of SAFE Shareholders; (ii) the approval of various matters related to the Proposed Transaction by the requisite majority of Company Shareholders; (iii) the completion by SAFE of certain financings; and (iv) other conditions customary for a transaction of this nature.
In connection with the Proposed Transaction, the Company intends to change its name to a name to be determined by SAFE and to replace all directors and officers of the Company on the effective date of the Proposed Transaction with nominees of SAFE, subject to applicable securities laws and exchange policies.
There can be no assurance that the Proposed Transaction will be completed on the terms proposed or at all.
Further Information
Further details about the Proposed Transaction and the Company (as it exists upon completion of the Proposed Transaction, the “Resulting Issuer”) will be included in subsequent continuous disclosure documents and filed by the Company and SAFE in respect of the Proposed Transaction.
Investors are cautioned that, except as disclosed in the listing statement (or other disclosure document prepared by the Company) in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon.
About SAFE
SAFE is a life sciences company composed of a proficient team of entrepreneurs, leaders in the pharmaceutical industry, and former high-ranking government officials. The company is focused on building a robust portfolio of harm reduction solutions that take a prevent, protect and prevail approach.
SAFE’s current portfolio of harm reduction solutions includes an FDA cleared neuromodulation device for opioid withdrawal symptoms, life saving naloxone hydrochloride products, fentanyl testing devices and a pipeline of synthetic agonists aimed at treating addiction.
Cautionary Note Regarding Forward-Looking Statements:
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.
Forward-looking statements in this document include, among others, statements relating to expectations regarding the completion of the Proposed Transaction (including all required approvals), the entrance into of definitive transaction documentation, the financings of SAFE, the business plans of the Resulting Issuer and other statements that are not historical facts. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) that there is no assurance that the parties hereto will obtain the requisite director, shareholder and regulatory approvals for the Proposed Transaction; (b) there is no assurance that the SAFE financings will be completed or as to the actual offering price or gross proceeds to be raised in connection therewith; (c) following completion of the Proposed Transaction, the Resulting Issuer may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (d) compliance with extensive government regulation; (e) domestic and foreign laws and regulations could adversely affect the Resulting Issuer’s business and results of operations; (f) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Resulting Issuer's securities, regardless of its operating performance; (g) adverse changes in the public perception of companies involved in fentanyl testing; and (i) decreases in the prevailing prices for health sciences companies in the markets that the Resulting Issuer will operate in.
The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
On behalf of the Board of Directors
TJ Finch
CEO, CFO and Director
Tel: 647-738-8063
Email: [email protected]
TJ Finch
1348521 B.C. Ltd.
+1 647-738-8063
email us here
